Anti-IL-17, Anti-IL-23 Rxs Show Sustained Psoriasis Control

Both an approved anti-IL-17 therapy and an experimental oral anti-IL-23 therapy appeared to achieve relatively undiminished rates of psoriasis control in extension studies.

Related Keywords

Pennsylvania ,United States ,New York ,American ,Laurak Ferris ,Mark Lebwohl ,Department Of Dermatology ,Icahn School Of Medicine At Mount Sinai ,American Academy Of Dermatology ,University Of Pittsburgh Medical Center ,American Academy ,Psoriasis Area ,Severity Index ,Icahn School ,Mount Sinai ,Apparent Loss ,Benefit Over ,Pittsburgh Medical Center ,New England Journal ,First Potential Oral ,